

ASX Code	IMU
Recent Stock Price (Feb 05)	26.5c
Market Capitalisation	\$34.5 m
Number of shares on issue	130m
Cash Feb 05	\$5.0m
Sector	Pharmaceuticals & Biotechnology

Imugene is an animal health company commercialising biological products for production animals (pigs, poultry and cattle). The range of biological products improve animal health and production without the use of antibiotics, chemicals or hormones, promoting the production of residue free consumer food products.

LEAD PRODUCTS

1. **Poultry Productivity Enhancer** (Adenoviral vectors)—increases natural immunity and protects against viral and bacterial diseases, promotes growth—market size > US\$1 B pa *licensee to commercialise*
2. **Pig Vaccines** (Adenoviral vectors)—PRRS vaccine has undergone successful pig trials and is being fast-tracked—market size US\$200 M - \$400 M pa *licensee to commercialise*

Another vaccine against a major respiratory disease is being evaluated for major markets—market size \$300 M pa *licensee to commercialise*
3. **Pig *E coli*** Preventative (Receptor Mimic Technology RMT) treats and prevents infectious gut diseases in pigs— replacement for antibiotics and anti-microbial—first pig product market size > US\$450 M pa *Imugene to commercialise*

INVESTMENT HIGHLIGHTS

- ❑ Consumers and regulators around the world are demanding safe alternatives to the use of antibiotics and chemicals in production animals. Antibiotic chemical and hormone residues in retail meat pose health risks to consumers who eat residue contaminated meat
- ❑ Imugene's products are biologicals and vaccines, not drugs, chemicals or hormones.
- ❑ Approval timelines for animal products are much shorter than for human products and biological products are quicker to get to market than chemicals. Imugene is rapidly commercialising animal health products focused on large markets with unmet need and low competition
- ❑ Multiple trials confirm the efficacy of Imugene's vaccine for the major disease of pigs—PRRS—sparking interest from multinational animal health companies
- ❑ Trials of Imugene's key chicken productivity enhancer results in extraordinary 13.75% extra growth with 11.7% improvement in Food Conversion Ratio. These weight gains exceed current industry best practice by up to 15.8%
- ❑ Merial (a joint venture between Merck and Aventis) continues evaluation of three Imugene products
- ❑ Product approvals in the key US market are likely to be via the US Department of Agriculture (USDA), not the US Food and Drug Administration. This typically speeds commercialisation significantly
- ❑ Imugene will outsource RMT product manufacture to decrease risk and save time and money



OTHER PRODUCTS under development

Pig Productivity Enhancer (Adenoviral vector) increases natural immunity and protects against viral and bacterial diseases, promotes growth *licensee to commercialise*

Poultry anti-toxin (RMT receptor mimic) treating infectious diseases in poultry—highly effective replacement for antibiotics *Imugene to commercialise*

Cattle anti-toxin (RMT receptor mimic) treating infectious diseases in cattle—highly effective replacement for antibiotics *Imugene to commercialise*

Avian influenza vaccine (Adenoviral vector)—birds/poultry *Imugene to commercialise*

TECHNOLOGY

Adenoviral Vectors treat or prevent major infectious diseases affecting pigs & chickens as well as naturally enhancing the immune system to prevent viruses and bacteria from causing disease and reducing growth. The technology uses harmless viral vectors to deliver information to the cells of an animal. The cells respond by mounting an immune response that protects the animal or bird against future infections.

Principal Advantages:

- ✓ Biological not chemical
- ✓ Administered through drinking water or feed
- ✓ Safe, effective, no residue
- ✓ Inexpensive to produce in existing facilities
- ✓ Minimal regulatory requirements—low hurdles = very short approvals process

Patents granted and pending worldwide

Receptor Mimic (RMT) products treat and prevent gastrointestinal diseases in production animals—particularly diarrhoeal diseases caused by bacteria such as E.coli. Receptor mimic products act as an extremely efficient biological 'sponge', binding toxins or disease causing organisms and harmlessly carrying them out of the body. Unlike new or existing antibiotics or antimicrobials, there is no potential for food residues, no chance of resistance developing and the products are safe for widespread use in all mammalian species.

Principal Advantages:

- ✓ Biological not chemical
- ✓ Administered through drinking water or feed
- ✓ Safe, effective, no residue
- ✓ Inexpensive to produce in existing facilities
- ✓ Replacement for antibiotics & anti-microbials

Patents in major territories granted; other territories under review or pending

Major Shareholders

Portfolio Partners Limited – 9.8%
Graham Dowland – 5.2%

Queensland Investment Corporation – 6.2%
Warwick Lamb – 4.9%

Executive Management

Executive Chairman: Mr Graham Dowland
Chief Scientific Officer: Dr Mike Sheppard

Managing Director: Dr Warwick Lamb
Chief Operating Officer: Dr Paul MacLeman

CONTACT DETAILS

www.imugene.com

Level 1, 14 – 20 Delhi Road, NORTH RYDE, NSW 2113
Telephone: +61 2 9870 7330 Facsimile: +61 2 9888 9338
ABN: 99 009 179 551

Disclaimer: This Summary is dated 15 February 2005 and contains statements that are prospective in nature. These are based on management's current expectations. The statements relating to future events may differ from actual future events due to the various risks faced by Imugene in the development of the products listed herein. Imugene makes no warranty or representation as to the accuracy or completeness of the statements made in this Summary and expressly excludes all liability whatsoever, in negligence or otherwise, for any loss or damage suffered as a result of the statements being inaccurate or incomplete in any way for any reason.